← Back

Beijing Bohui Innovation Technology Co Ltd

Beijing Bohui Innovation Biotechnology Group Co., Ltd. researches, develops, produces, sells, and services in-vitro diagnostic products in China and internationally. Its offerings include human immunoglobulin for rabies, tetanus, hepatitis B, and intravenous injections; human serum albumin; human prothrombin complex and human coagulation factor VIII; and rabies vaccine. The company also provides molecular diagnostics platforms such as the Automatic Real-time Fluorescent Nucleic Acid Cartridge Analyzer (BHQ-III) and the GenPlex BHF-VI Nucleic Acid Chip Analyzer, along with trace element analyzers, fluorescence immunoassay analyzers, quantum dot analyzers, and detection kits for respiratory, intestinal, and reproductive infections, trace element testing, and allergen testing. In addition, it offers mass spectrometers, plate readers, standardized ion sources, and flash, process, and preparative purification systems. Formerly Beijing Bohui Innovation Biotechnology Co., Ltd., it changed its name to Beijing Bohui Innovation Biotechnology Group Co., Ltd. in August 2021, was founded in 2001, and is headquartered in Beijing, China.

Price · split & dividend adjusted
News & notes moving 300318.CS
300318.CS3

Bohui Innovation reports net loss of 15.61 million yuan in 2026 interim results

Bohui Innovation released its 2026 interim report. Total operating revenue was 396 million yuan, down 2.09 percent year on year, and net profit attributable to the parent company was a loss of 15.61 million yuan. Net cash flow from operating activities was a negative 36.65 million yuan. The asset-liability ratio was 51.06 percent, gross margin was 32.78 percent, return on equity was negative 1.23 percent, and diluted earnings per share was negative 0.02 yuan. The company had 29,300 shareholders, and the top ten shareholders held 61.39 percent of total share capital.
Jiemian·24dRead more →